Cargando…

DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay

Radiopharmaceuticals used for diagnosis or therapy induce DNA strand breaks, which may be detectable by single-cell gel electrophoresis (called comet assay). Blood was taken from patients before and at different time points after treatment with radiopharmaceuticals; blood cells were investigated by...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmeiser, Heinz H, Muehlbauer, Karl-Rudolf, Mier, Walter, Baranski, Ann-Christin, Neels, Oliver, Dimitrakopoulou-Strauss, Antonia, Schmezer, Peter, Kratochwil, Clemens, Bruchertseifer, Frank, Morgenstern, Alfred, Kopka, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6753384/
https://www.ncbi.nlm.nih.gov/pubmed/31107537
http://dx.doi.org/10.1093/mutage/gez007
_version_ 1783452890998767616
author Schmeiser, Heinz H
Muehlbauer, Karl-Rudolf
Mier, Walter
Baranski, Ann-Christin
Neels, Oliver
Dimitrakopoulou-Strauss, Antonia
Schmezer, Peter
Kratochwil, Clemens
Bruchertseifer, Frank
Morgenstern, Alfred
Kopka, Klaus
author_facet Schmeiser, Heinz H
Muehlbauer, Karl-Rudolf
Mier, Walter
Baranski, Ann-Christin
Neels, Oliver
Dimitrakopoulou-Strauss, Antonia
Schmezer, Peter
Kratochwil, Clemens
Bruchertseifer, Frank
Morgenstern, Alfred
Kopka, Klaus
author_sort Schmeiser, Heinz H
collection PubMed
description Radiopharmaceuticals used for diagnosis or therapy induce DNA strand breaks, which may be detectable by single-cell gel electrophoresis (called comet assay). Blood was taken from patients before and at different time points after treatment with radiopharmaceuticals; blood cells were investigated by the comet assay using the percentage of DNA in the tail as the critical parameter. Whereas [(225)Ac]Ac-prostate-specific membrane antigen (PSMA)-617 alpha therapy showed no difference relative to the blood sample taken before treatment, beta therapy with [(177)Lu]Lu-PSMA-617 3 h post-injection revealed a small but significant increase in DNA strand breaks. In blood of patients who underwent positron emission tomography (PET) with either [(18)F]2-fluor-2-deoxy-D-glucose (FDG) or [(68)Ga]Ga-PSMA-11, an increase of DNA migration determined by the comet assay was not found when analysed at different time points (2–70 min) after intravenous tracer injection. Human whole blood was incubated with the targeted clinically relevant therapeutic radiopharmaceuticals [(225)Ac]Ac-PSMA-617, [(177)Lu]Lu-PSMA-617 and [(90)Y]Y-DOTA(0)-Phe(1)-Tyr(3)-octreotide (DOTA-TOC) at different activity concentrations (kBq/ml) for 5 days and then analysed by the comet assay. DNA damage increased with higher concentrations of all radiolabeled compounds tested. [(177)Lu]Lu-PSMA-617 caused higher blood cell radiotoxicity than equal activity concentrations of [(90)Y]Y-DOTA-TOC. Likewise, whole human blood was exposed to the positron emitters [(18)F]FDG and [(68)Ga]Ga-PSMA-11 in vitro for 24 h with activity concentrations ranging between 5 and 40 MBq/ml. The same activity concentration dependent elevated DNA migration was observed for both compounds although decay energies are different. This study demonstrated that the amount of DNA damage detected by the comet assay in whole human blood is similar among different positron emitters and divergent by a factor of 200 between alpha particles and beta radiation.
format Online
Article
Text
id pubmed-6753384
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-67533842019-09-25 DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay Schmeiser, Heinz H Muehlbauer, Karl-Rudolf Mier, Walter Baranski, Ann-Christin Neels, Oliver Dimitrakopoulou-Strauss, Antonia Schmezer, Peter Kratochwil, Clemens Bruchertseifer, Frank Morgenstern, Alfred Kopka, Klaus Mutagenesis Original Manuscripts Radiopharmaceuticals used for diagnosis or therapy induce DNA strand breaks, which may be detectable by single-cell gel electrophoresis (called comet assay). Blood was taken from patients before and at different time points after treatment with radiopharmaceuticals; blood cells were investigated by the comet assay using the percentage of DNA in the tail as the critical parameter. Whereas [(225)Ac]Ac-prostate-specific membrane antigen (PSMA)-617 alpha therapy showed no difference relative to the blood sample taken before treatment, beta therapy with [(177)Lu]Lu-PSMA-617 3 h post-injection revealed a small but significant increase in DNA strand breaks. In blood of patients who underwent positron emission tomography (PET) with either [(18)F]2-fluor-2-deoxy-D-glucose (FDG) or [(68)Ga]Ga-PSMA-11, an increase of DNA migration determined by the comet assay was not found when analysed at different time points (2–70 min) after intravenous tracer injection. Human whole blood was incubated with the targeted clinically relevant therapeutic radiopharmaceuticals [(225)Ac]Ac-PSMA-617, [(177)Lu]Lu-PSMA-617 and [(90)Y]Y-DOTA(0)-Phe(1)-Tyr(3)-octreotide (DOTA-TOC) at different activity concentrations (kBq/ml) for 5 days and then analysed by the comet assay. DNA damage increased with higher concentrations of all radiolabeled compounds tested. [(177)Lu]Lu-PSMA-617 caused higher blood cell radiotoxicity than equal activity concentrations of [(90)Y]Y-DOTA-TOC. Likewise, whole human blood was exposed to the positron emitters [(18)F]FDG and [(68)Ga]Ga-PSMA-11 in vitro for 24 h with activity concentrations ranging between 5 and 40 MBq/ml. The same activity concentration dependent elevated DNA migration was observed for both compounds although decay energies are different. This study demonstrated that the amount of DNA damage detected by the comet assay in whole human blood is similar among different positron emitters and divergent by a factor of 200 between alpha particles and beta radiation. Oxford University Press 2019-09 2019-05-20 /pmc/articles/PMC6753384/ /pubmed/31107537 http://dx.doi.org/10.1093/mutage/gez007 Text en © The Author 2019. Published by Oxford University Press on behalf of the UK Environmental Mutagen Society. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Manuscripts
Schmeiser, Heinz H
Muehlbauer, Karl-Rudolf
Mier, Walter
Baranski, Ann-Christin
Neels, Oliver
Dimitrakopoulou-Strauss, Antonia
Schmezer, Peter
Kratochwil, Clemens
Bruchertseifer, Frank
Morgenstern, Alfred
Kopka, Klaus
DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay
title DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay
title_full DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay
title_fullStr DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay
title_full_unstemmed DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay
title_short DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay
title_sort dna damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay
topic Original Manuscripts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6753384/
https://www.ncbi.nlm.nih.gov/pubmed/31107537
http://dx.doi.org/10.1093/mutage/gez007
work_keys_str_mv AT schmeiserheinzh dnadamageinhumanwholebloodcausedbyradiopharmaceuticalsevaluatedbythecometassay
AT muehlbauerkarlrudolf dnadamageinhumanwholebloodcausedbyradiopharmaceuticalsevaluatedbythecometassay
AT mierwalter dnadamageinhumanwholebloodcausedbyradiopharmaceuticalsevaluatedbythecometassay
AT baranskiannchristin dnadamageinhumanwholebloodcausedbyradiopharmaceuticalsevaluatedbythecometassay
AT neelsoliver dnadamageinhumanwholebloodcausedbyradiopharmaceuticalsevaluatedbythecometassay
AT dimitrakopouloustraussantonia dnadamageinhumanwholebloodcausedbyradiopharmaceuticalsevaluatedbythecometassay
AT schmezerpeter dnadamageinhumanwholebloodcausedbyradiopharmaceuticalsevaluatedbythecometassay
AT kratochwilclemens dnadamageinhumanwholebloodcausedbyradiopharmaceuticalsevaluatedbythecometassay
AT bruchertseiferfrank dnadamageinhumanwholebloodcausedbyradiopharmaceuticalsevaluatedbythecometassay
AT morgensternalfred dnadamageinhumanwholebloodcausedbyradiopharmaceuticalsevaluatedbythecometassay
AT kopkaklaus dnadamageinhumanwholebloodcausedbyradiopharmaceuticalsevaluatedbythecometassay